Paltusotine Hydrochloride Patent Expiration

Paltusotine Hydrochloride was first introduced by Crinetics Pharmaceuticals Inc in its drug Palsonify on Sep 25, 2025.


Paltusotine Hydrochloride Patents

Given below is the list of patents protecting Paltusotine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Palsonify US12208092 Mar 25, 2044 Crinetics
Palsonify US11266641 Sep 07, 2041 Crinetics
Palsonify US11957674 Sep 07, 2041 Crinetics
Palsonify US10464918 Jan 16, 2039 Crinetics
Palsonify US10351547 Jul 12, 2037 Crinetics
Palsonify US10597377 Jul 12, 2037 Crinetics
Palsonify US10875839 Jul 12, 2037 Crinetics
Palsonify US11414397 Jul 12, 2037 Crinetics
Palsonify US9896432 Jul 12, 2037 Crinetics



Paltusotine Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Paltusotine Hydrochloride Generic API Manufacturers

Given below is the list of companies who have filed for Paltusotine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.